Human loss-of-function gonadotropin-releasing hormone receptor mutants retain wild-type receptors in the endoplasmic reticulum: Molecular basis of the dominant-negative effect

Shaun P. Brothers, Anda Cornea, Jo Ann Janovick, P. Michael Conn

    Research output: Contribution to journalArticle

    87 Citations (Scopus)

    Abstract

    The GnRH receptor (GnRHR) is a heptahelical G protein-coupled receptor found in the plasma membrane of pituitary gonadotropes. GnRHR mutants isolated from patients with hypogonadotropic hypogonadism (HH) are frequently mislocalized proteins that can be restored to function by pharmacological chaperones. Non-functional HH mutants inhibit ligand binding and ligand-activated second messenger production by wild-type (WT) receptor when both are coexpressed in vitro. In this study, confocal microscopy of fluorescently labeled GnRHR was used to show that the dominant-negative effect, which occurs for human (but not for rodent) GnRHR, results from WT receptor retention in the endoplasmic reticulum by mislocalized mutants. Mutants hGnRHR(E90K), hGnRHR(L266R), and hGnRHR(S168R) were selected for study because they are known to be fully rescuable, partially rescuable, or nonrescuable (respectively) by a specific pharmacological chaperone. This chaperone corrects folding errors and promotes correct intracellular routing. Using this drug we showed that correcting routing of the mutant protein also rescues the WT receptor. Because of the large number of human diseases that appear to be caused by defective protein folding and subsequent mislocalization, it is likely that endoplasmic reticulum retention is a common cause of dominant-negative actions for other diseases involving G protein-coupled receptors, as appears to be the case in HH and for which there exists a potential therapeutic agent.

    Original languageEnglish (US)
    Pages (from-to)1787-1797
    Number of pages11
    JournalMolecular Endocrinology
    Volume18
    Issue number7
    DOIs
    StatePublished - Jul 2004

    Fingerprint

    LHRH Receptors
    Endoplasmic Reticulum
    Hypogonadism
    G-Protein-Coupled Receptors
    Pharmacology
    Ligands
    Protein Folding
    Second Messenger Systems
    Mutant Proteins
    Confocal Microscopy
    Rodentia
    Cell Membrane
    Pharmaceutical Preparations
    Proteins

    ASJC Scopus subject areas

    • Molecular Biology
    • Endocrinology, Diabetes and Metabolism

    Cite this

    Human loss-of-function gonadotropin-releasing hormone receptor mutants retain wild-type receptors in the endoplasmic reticulum : Molecular basis of the dominant-negative effect. / Brothers, Shaun P.; Cornea, Anda; Janovick, Jo Ann; Conn, P. Michael.

    In: Molecular Endocrinology, Vol. 18, No. 7, 07.2004, p. 1787-1797.

    Research output: Contribution to journalArticle

    @article{c1300e992c8043d39f114cac2f9ed28d,
    title = "Human loss-of-function gonadotropin-releasing hormone receptor mutants retain wild-type receptors in the endoplasmic reticulum: Molecular basis of the dominant-negative effect",
    abstract = "The GnRH receptor (GnRHR) is a heptahelical G protein-coupled receptor found in the plasma membrane of pituitary gonadotropes. GnRHR mutants isolated from patients with hypogonadotropic hypogonadism (HH) are frequently mislocalized proteins that can be restored to function by pharmacological chaperones. Non-functional HH mutants inhibit ligand binding and ligand-activated second messenger production by wild-type (WT) receptor when both are coexpressed in vitro. In this study, confocal microscopy of fluorescently labeled GnRHR was used to show that the dominant-negative effect, which occurs for human (but not for rodent) GnRHR, results from WT receptor retention in the endoplasmic reticulum by mislocalized mutants. Mutants hGnRHR(E90K), hGnRHR(L266R), and hGnRHR(S168R) were selected for study because they are known to be fully rescuable, partially rescuable, or nonrescuable (respectively) by a specific pharmacological chaperone. This chaperone corrects folding errors and promotes correct intracellular routing. Using this drug we showed that correcting routing of the mutant protein also rescues the WT receptor. Because of the large number of human diseases that appear to be caused by defective protein folding and subsequent mislocalization, it is likely that endoplasmic reticulum retention is a common cause of dominant-negative actions for other diseases involving G protein-coupled receptors, as appears to be the case in HH and for which there exists a potential therapeutic agent.",
    author = "Brothers, {Shaun P.} and Anda Cornea and Janovick, {Jo Ann} and Conn, {P. Michael}",
    year = "2004",
    month = "7",
    doi = "10.1210/me.2004-0091",
    language = "English (US)",
    volume = "18",
    pages = "1787--1797",
    journal = "Molecular Endocrinology",
    issn = "0888-8809",
    publisher = "The Endocrine Society",
    number = "7",

    }

    TY - JOUR

    T1 - Human loss-of-function gonadotropin-releasing hormone receptor mutants retain wild-type receptors in the endoplasmic reticulum

    T2 - Molecular basis of the dominant-negative effect

    AU - Brothers, Shaun P.

    AU - Cornea, Anda

    AU - Janovick, Jo Ann

    AU - Conn, P. Michael

    PY - 2004/7

    Y1 - 2004/7

    N2 - The GnRH receptor (GnRHR) is a heptahelical G protein-coupled receptor found in the plasma membrane of pituitary gonadotropes. GnRHR mutants isolated from patients with hypogonadotropic hypogonadism (HH) are frequently mislocalized proteins that can be restored to function by pharmacological chaperones. Non-functional HH mutants inhibit ligand binding and ligand-activated second messenger production by wild-type (WT) receptor when both are coexpressed in vitro. In this study, confocal microscopy of fluorescently labeled GnRHR was used to show that the dominant-negative effect, which occurs for human (but not for rodent) GnRHR, results from WT receptor retention in the endoplasmic reticulum by mislocalized mutants. Mutants hGnRHR(E90K), hGnRHR(L266R), and hGnRHR(S168R) were selected for study because they are known to be fully rescuable, partially rescuable, or nonrescuable (respectively) by a specific pharmacological chaperone. This chaperone corrects folding errors and promotes correct intracellular routing. Using this drug we showed that correcting routing of the mutant protein also rescues the WT receptor. Because of the large number of human diseases that appear to be caused by defective protein folding and subsequent mislocalization, it is likely that endoplasmic reticulum retention is a common cause of dominant-negative actions for other diseases involving G protein-coupled receptors, as appears to be the case in HH and for which there exists a potential therapeutic agent.

    AB - The GnRH receptor (GnRHR) is a heptahelical G protein-coupled receptor found in the plasma membrane of pituitary gonadotropes. GnRHR mutants isolated from patients with hypogonadotropic hypogonadism (HH) are frequently mislocalized proteins that can be restored to function by pharmacological chaperones. Non-functional HH mutants inhibit ligand binding and ligand-activated second messenger production by wild-type (WT) receptor when both are coexpressed in vitro. In this study, confocal microscopy of fluorescently labeled GnRHR was used to show that the dominant-negative effect, which occurs for human (but not for rodent) GnRHR, results from WT receptor retention in the endoplasmic reticulum by mislocalized mutants. Mutants hGnRHR(E90K), hGnRHR(L266R), and hGnRHR(S168R) were selected for study because they are known to be fully rescuable, partially rescuable, or nonrescuable (respectively) by a specific pharmacological chaperone. This chaperone corrects folding errors and promotes correct intracellular routing. Using this drug we showed that correcting routing of the mutant protein also rescues the WT receptor. Because of the large number of human diseases that appear to be caused by defective protein folding and subsequent mislocalization, it is likely that endoplasmic reticulum retention is a common cause of dominant-negative actions for other diseases involving G protein-coupled receptors, as appears to be the case in HH and for which there exists a potential therapeutic agent.

    UR - http://www.scopus.com/inward/record.url?scp=3042800569&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=3042800569&partnerID=8YFLogxK

    U2 - 10.1210/me.2004-0091

    DO - 10.1210/me.2004-0091

    M3 - Article

    C2 - 15105440

    AN - SCOPUS:3042800569

    VL - 18

    SP - 1787

    EP - 1797

    JO - Molecular Endocrinology

    JF - Molecular Endocrinology

    SN - 0888-8809

    IS - 7

    ER -